

**PRESS RELEASE**

# Probi's Annual General Meeting 2022

On Probi's Annual General Meeting on 5 May 2022, the following was resolved:

- The Annual General Meeting approved the Annual Report and the Board's proposal on a dividend for the financial year 2021 corresponding to SEK 1.30 per share. The record date was set to 9 May 2022.
- The Annual General Meeting discharged the Board members and the CEO from liability for the financial year 2021.
- The Annual General Meeting resolved that the Board shall consist of five members without any deputies. The meeting re-elected the Board members Jean-Yves Parisot, Jörn Andreas, Irène Corthésy Malnoë, Charlotte Hansson and Malin Ruijsenaars. Jean-Yves Parisot was re-elected as Chairman of the Board.
- The Annual General Meeting resolved that Board fees shall be paid in the amount of SEK 540,000 (SEK 520,000) to the Chairman and SEK 270,000 (SEK 260,000) to each of the other members. In addition, fee for committee work was determined to SEK 120,000 (SEK 120,000) to the Chairman of the Audit Committee and SEK 50,000 (SEK 50,000) to the other members, and SEK 30,000 (SEK 30,000) to Chairman of the Remuneration Committee and SEK 20,000 (SEK 20,000) to the other members.
- The Annual General Meeting re-elected the registered public accounting firm Ernst & Young AB, which had informed that Peter Gunnarsson should be the auditor in charge, and resolved on fees to the auditor according to approved account.
- The Annual General Meeting resolved to approve the Board's remuneration report.
- The Board was authorized, in accordance with its proposal, for the period until the next AGM and on one or several occasions, to resolve on the issue of not more than 1,165,000 shares.
- The Annual General Meeting appointed a nomination committee ahead of the Annual General Meeting 2023 consisting of Heinz-Jürgen Bertram (Symrise), Marianne Flink (Fourth Swedish National Pension Fund), Monica Åsmyr (Swedbank Robur funds) and Bengt Jeppsson (Professor, Surgical Faculty, Lund University, representing the minor shareholders).

Presentation from the CEO is available on <https://www.probi.com/investor-relations/presentations/>

**For further information, please contact:**

Tom Rönnlund, CEO: tel + 46 46 286 89 40, e-mail: [trd@probi.com](mailto:trd@probi.com)

Henrik Lundkvist, CFO, Probi, Phone +46 46 286 89 41, E-mail: [henrik.lundkvist@probi.com](mailto:henrik.lundkvist@probi.com)

**ABOUT PROBI**

Probi® is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 658 m in 2021. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,800 shareholders on December 31, 2021.